Company intelligence
Cancer Research Horizons
We are Cancer Research UK's innovation arm, translating discovery into breakthrough treatments.
About Cancer Research Horizons
Cancer Research Horizons is Cancer Research UK's innovation engine. We take scientific breakthroughs from the lab bench to the bedside, translating them into effective treatments and diagnostics for cancer patients. To date, we’ve played an instrumental role in forming over 70 start-ups and bringing 14 new cancer drugs to market, borne out of our pioneering research. With exclusive rights to over £400m of world-class cancer research we’re a unique and powerful partner in the fight to beat cancer. We work closely with academia and industry to bridge the gap between research and the market, delivering maximum impact for patients. Every penny we make goes back into developing the next breakthroughs, helping bring forward the day when all cancer is conquered.
Verified activity
Signals from Cancer Research Horizons
8 published signals
Strategy & Corporate Development
Cancer Research Horizons announced the recent acquisition of portfolio company Myricx Bio by Novartis.
Reported by Cancer Research Horizons
Capital & Finance
Cancer Research Horizons portfolio company Trogenix raised £70m to develop new therapies for treatment-resistant cancers.
Reported by Cancer Research Horizons
Capital & Finance
Cancer Research Horizons leveraged more than £3.5bn in additional investment to support the development of new cancer innovations.
Reported by Cancer Research Horizons
Research & Knowledge
Cancer Research Horizons offers tailored support for researchers to identify therapeutic targets, mechanisms of drug resistance, and more through the Functional Genomics Centre.
Reported by Cancer Research Horizons
Presence & Recognition
Cancer Research Horizons invites researchers to apply by 28 September for support.
Reported by Cancer Research Horizons
Research & Knowledge
Cancer Research Horizons published an interview with Rob Williams, former Chief Drug Development Scientist at Cancer Research UK's Centre for Drug development, discussing lessons learned from over 30 drug candidates progressing into first-in-human trials.
Reported by Cancer Research Horizons
Research & Knowledge
Cancer Research Horizons is inviting applications for a project proposal to C-Further for early-stage childhood cancer discovery with potential to underpin new treatments.
Reported by Cancer Research Horizons
Presence & Recognition
Cancer Research Horizons is participating in the ELRIG Drug Discovery Conference 2026 track on targeted potency, radioligands, and bioconjugates.
Reported by Cancer Research Horizons